-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, many postoperative patients have consulted me about postoperative adjuvant treatment, especially for stage Ib.
Recently, many postoperative patients have consulted me about postoperative adjuvant treatment, especially for stage Ib.
Medical history features: female, 53 years old, after radical resection of right upper lobe adenocarcinoma.
Postoperative pathology: invasive lung adenocarcinoma, 1.
It suggests that the pleura is affected.
First of all, although the tumor itself is only 1cm, the attending doctor according to the pathology suggested that there is pleural invasion, and the patient is staged as pT2N0M0, which is stage Ib.
second question.
Even if there is pleural invasion, we cannot generalize these patients.
Third, in the 2020 China CSCO guidelines, it is clearly stated that for stage Ib non-small cell lung cancer, including lung cancer with high-risk factors, adjuvant chemotherapy is not recommended because it is believed that chemotherapy cannot improve the prognosis and reduce the risk of recurrence.
Blood vessel
However, the 2021 NCCN guidelines recommend adjuvant chemotherapy for stage Ib non-small cell lung cancer patients with high-risk factors after surgery, and recommend that patients who are not suitable for platinum-containing dual-drug regimens can receive oral osimertinib 80 mg/day.
ADAURA
Therefore, after a comprehensive evaluation, my recommendations for this patient are as follows:
1.
2.
It is not easy to be a thoracic surgeon.
Manage
messages here
